Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Infectious Diseases |
| Vol/bind | 199 |
| Udgave nummer | 7 |
| Sider (fra-til) | 926-35 |
| Antal sider | 9 |
| ISSN | 0022-1899 |
| DOI | |
| Status | Udgivet - 2009 |
Bibliografisk note
Keywords: Adolescent; Adult; Alphapapillomavirus; Female; Humans; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Neoplasms; Young AdultCitationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
I: Journal of Infectious Diseases, Bind 199, Nr. 7, 2009, s. 926-35.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years
AU - Brown, Darron R
AU - Kjaer, Susanne K
AU - Sigurdsson, Kristján
AU - Iversen, Ole-Erik
AU - Hernandez-Avila, Mauricio
AU - Wheeler, Cosette M
AU - Perez, Gonzalo
AU - Koutsky, Laura A
AU - Tay, Eng Hseon
AU - Garcia, Patricía
AU - Ault, Kevin A
AU - Garland, Suzanne M
AU - Leodolter, Sepp
AU - Olsson, Sven-Eric
AU - Tang, Grace W K
AU - Ferris, Daron G
AU - Paavonen, Jorma
AU - Steben, Marc
AU - Bosch, F Xavier
AU - Dillner, Joakim
AU - Joura, Elmar A
AU - Kurman, Robert J
AU - Majewski, Slawomir
AU - Muñoz, Nubia
AU - Myers, Evan R
AU - Villa, Luisa L
AU - Taddeo, Frank J
AU - Roberts, Christine
AU - Tadesse, Amha
AU - Bryan, Janine
AU - Lupinacci, Lisa C
AU - Giacoletti, Katherine E D
AU - Sings, Heather L
AU - James, Margaret
AU - Hesley, Teresa M
AU - Barr, Eliav
N1 - Keywords: Adolescent; Adult; Alphapapillomavirus; Female; Humans; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Neoplasms; Young Adult
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. METHODS: We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotyping was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. RESULTS: Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. CONCLUSIONS: HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for approximately 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00092521 , NCT00092534 , and NCT00092482.
AB - BACKGROUND: Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. METHODS: We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotyping was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. RESULTS: Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. CONCLUSIONS: HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for approximately 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00092521 , NCT00092534 , and NCT00092482.
U2 - 10.1086/597307
DO - 10.1086/597307
M3 - Journal article
C2 - 19236279
SN - 0022-1899
VL - 199
SP - 926
EP - 935
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -